World Breast Cancer Research and Prevention Day – A study with Mediteanox®

At Euromed SA, we seize this occasion to highlight the importance of supporting this cause, not just today, but every day of the year.

We are committed to advancing science by backing the dedicated research teams who tirelessly strive to enhance prevention, early detection, and the development of innovative treatments. We stand together, offering our heartfelt support, recognising that each story is unique and deserving of empathy and understanding during this process.

In honor of this day, we would like to share a study conducted with Mediteanox® in women with breast cancer.

This triple-blind clinical trial explored the effects of hydroxytyrosol (HT), a potent antioxidant, on women undergoing chemotherapy for luminal subtype breast cancer. The HT used in the study was administered through Mediteanox®, a natural extract derived from olives fruit grown in Jaén, Spain. Mediteanox® is produced using our patented Pure-Hydro Process®, which utilizes ultrapure water.

The study found that women who received a daily dose of 15 mg of HT (equivalent to 99 mg of Mediteanox®), particularly during treatment with epirubicin and cyclophosphamide, exhibited a significant reduction in plasma levels of TIMP-1, a protein associated with cancer progression, compared to those taking a placebo. Although more research is needed, these results suggest that HT may positively influence TIMP-1 levels in this subtype of breast cancer, potentially leading to improved therapeutic outcomes for patients. Additionally, the antioxidant properties of HT may be beneficial during chemotherapy treatment.